US 12,440,560 B2
Substituted pyrimidines as vaccine adjuvants
Hidenori Kimura, Tokyo (JP); Hitoshi Ban, Osaka (JP); Yoshiaki Isobe, Osaka (JP); and Hitoshi Watanabe, Osaka (JP)
Assigned to Sumitomo Pharma Co., Ltd., Osaka (JP)
Filed by Sumitomo Pharma Co., Ltd., Osaka (JP)
Filed on Jan. 23, 2024, as Appl. No. 18/420,017.
Application 18/420,017 is a division of application No. 17/583,933, filed on Jan. 25, 2022, granted, now 11,911,466.
Application 17/583,933 is a division of application No. 16/822,894, filed on Mar. 18, 2020, granted, now 11,266,738, issued on Mar. 8, 2022.
Application 16/822,894 is a continuation of application No. 15/766,560, granted, now 10,632,192, issued on Apr. 28, 2020, previously published as PCT/JP2016/079756, filed on Oct. 6, 2016.
Claims priority of application No. 2015-199750 (JP), filed on Oct. 7, 2015.
Prior Publication US 2024/0245766 A1, Jul. 25, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/505 (2006.01); A61K 39/00 (2006.01); A61K 39/39 (2006.01); A61P 37/04 (2006.01); C07D 239/49 (2006.01)
CPC A61K 39/39 (2013.01) [A61K 39/00 (2013.01); A61P 37/04 (2018.01); C07D 239/49 (2013.01); A61K 2039/505 (2013.01)] 7 Claims
 
1. A pharmaceutical composition comprising at least one pharmaceutically acceptable carrier or excipient and a compound selected from the group consisting of:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof.